ArticleNorthern clinics of Istanbul2026
Assessment of retinal and hearing impairments related to microvascular dysfunction in metabolic syndrome.
Article in Northern clinics of Istanbul, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetabolic syndrome (MetS) is a global health issue linked to both macrovascular and emerging microvascular complications. This study aimed to assess microvascular complications of MetS, including retinopathy and hearing loss.
methodsThis cross-sectional study included 102 adults (70 with MetS, 32 controls) from an internal medicine clinic. Participants underwent metabolic profiling and standardized eye and hearing evaluations, including fundoscopy, audiometry, and symptom screening. Sensory complications were analyzed in relation to MetS and its components using regression models.
resultsRetinal abnormalities were more common in the MetS group (50%) than in controls (18.7%) (p=0.007), with hypertension as the only independent predictor (OR=2.623, p=0.022). Sensorineural hearing loss affected 23.5% of participants and was linked to higher metabolic burden (p=0.038), though age and male sex were the main predictors. Tinnitus was more frequent in MetS patients (19% vs. 3%) (p=0.059), with triglycerides independently predicting its risk (OR=1.006, p=0.021). Vertigo occurred in 11.4% of MetS patients but not in controls (p=0.054), with hypertension showing borderline significance (OR=7.311, p=0.065).
conclusionMetabolic syndrome, particularly hypertension and dyslipidemia, is associated with increased risk of retinopathy, hearing loss, tinnitus, and vertigo. These findings suggest systemic metabolic dysfunction may impair microvascular structures in the eye and inner ear. Routine sensory screening in MetS patients may enable early detection and prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.